Cargando…

IL10-592位点AA基因型对HLA-10/10全相合无关供者异基因造血干细胞移植预后的影响

OBJECTIVE: To explore the impact of IL10-592 (rs1800872) single nucleic acid polymorphism (SNP) on the prognosis of HLA matched unrelated hematopoietic stem cell transplantation (HSCT). METHODS: The polymorphism of IL10-592 in 104 recipient-donor pairs and 100 healthy volunteers was analyzed with se...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348318/
https://www.ncbi.nlm.nih.gov/pubmed/27210870
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.05.004
_version_ 1783556788482736128
collection PubMed
description OBJECTIVE: To explore the impact of IL10-592 (rs1800872) single nucleic acid polymorphism (SNP) on the prognosis of HLA matched unrelated hematopoietic stem cell transplantation (HSCT). METHODS: The polymorphism of IL10-592 in 104 recipient-donor pairs and 100 healthy volunteers was analyzed with sequence based typing (SBT). RESULTS: When the genotype of IL10-592 in donors and recipients matched, AA/AA genotype had higher incidence of Ⅲ–Ⅳ aGVHD than AC/AC or CC/CC genotype (47.1%, 3.7%, 0, P=0.002). When the genotype of IL10-592 in donors and recipients mismatched, recipients with AC genotype or donors with AA genotype, there was significant different incidence of Ⅲ–ⅣaGVHD among donors or recipients with different genotype (P=0.046, P=0.041). The recipients with AA genotype had higher incidence of Ⅲ–Ⅳ aGVHD than AC or CC genotype (27.8% vs 10.2%, 11.1%; P=0.072), and higher incidence of intestinal aGVHD (22.2% vs 5.1%,11.1%; P=0.040), lower incidence of 2-year overall survival (OS: 48.2% vs 75.1%, 85.7%; P=0.002), lower incidence of 2 year disease free survival (DFS: 48.5% vs 66.3%, 76.2%; P=0.045). Patients had higher incidence of Ⅲ–Ⅳ aGVHD with donors of AA genotype than with donors of AC or CC genotype (26.5% vs 8.9%, 0; P=0.024), and higher incidence of intestinal aGVHD (20.4% vs 4.4%, 0; P=0.026). In multivariate analysis, the genotype of IL10-592AA in recipients and donors had increased risk of Ⅲ–Ⅳ aGVHD (OR=3.3, P=0.049; OR=3.9, P=0.043). There were no statistical differences on the incidence of cGVHD and relapse. CONCLUSION: In HLA-10/10 matched unrelated HSCT, the presence of IL10-592 AA genotype in recipients and/or donors is an adverse factor for Ⅲ–ⅣaGVHD, worse OS and 2-year DFS.
format Online
Article
Text
id pubmed-7348318
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73483182020-07-16 IL10-592位点AA基因型对HLA-10/10全相合无关供者异基因造血干细胞移植预后的影响 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To explore the impact of IL10-592 (rs1800872) single nucleic acid polymorphism (SNP) on the prognosis of HLA matched unrelated hematopoietic stem cell transplantation (HSCT). METHODS: The polymorphism of IL10-592 in 104 recipient-donor pairs and 100 healthy volunteers was analyzed with sequence based typing (SBT). RESULTS: When the genotype of IL10-592 in donors and recipients matched, AA/AA genotype had higher incidence of Ⅲ–Ⅳ aGVHD than AC/AC or CC/CC genotype (47.1%, 3.7%, 0, P=0.002). When the genotype of IL10-592 in donors and recipients mismatched, recipients with AC genotype or donors with AA genotype, there was significant different incidence of Ⅲ–ⅣaGVHD among donors or recipients with different genotype (P=0.046, P=0.041). The recipients with AA genotype had higher incidence of Ⅲ–Ⅳ aGVHD than AC or CC genotype (27.8% vs 10.2%, 11.1%; P=0.072), and higher incidence of intestinal aGVHD (22.2% vs 5.1%,11.1%; P=0.040), lower incidence of 2-year overall survival (OS: 48.2% vs 75.1%, 85.7%; P=0.002), lower incidence of 2 year disease free survival (DFS: 48.5% vs 66.3%, 76.2%; P=0.045). Patients had higher incidence of Ⅲ–Ⅳ aGVHD with donors of AA genotype than with donors of AC or CC genotype (26.5% vs 8.9%, 0; P=0.024), and higher incidence of intestinal aGVHD (20.4% vs 4.4%, 0; P=0.026). In multivariate analysis, the genotype of IL10-592AA in recipients and donors had increased risk of Ⅲ–Ⅳ aGVHD (OR=3.3, P=0.049; OR=3.9, P=0.043). There were no statistical differences on the incidence of cGVHD and relapse. CONCLUSION: In HLA-10/10 matched unrelated HSCT, the presence of IL10-592 AA genotype in recipients and/or donors is an adverse factor for Ⅲ–ⅣaGVHD, worse OS and 2-year DFS. Editorial office of Chinese Journal of Hematology 2016-05 /pmc/articles/PMC7348318/ /pubmed/27210870 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.05.004 Text en 2016年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
IL10-592位点AA基因型对HLA-10/10全相合无关供者异基因造血干细胞移植预后的影响
title IL10-592位点AA基因型对HLA-10/10全相合无关供者异基因造血干细胞移植预后的影响
title_full IL10-592位点AA基因型对HLA-10/10全相合无关供者异基因造血干细胞移植预后的影响
title_fullStr IL10-592位点AA基因型对HLA-10/10全相合无关供者异基因造血干细胞移植预后的影响
title_full_unstemmed IL10-592位点AA基因型对HLA-10/10全相合无关供者异基因造血干细胞移植预后的影响
title_short IL10-592位点AA基因型对HLA-10/10全相合无关供者异基因造血干细胞移植预后的影响
title_sort il10-592位点aa基因型对hla-10/10全相合无关供者异基因造血干细胞移植预后的影响
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348318/
https://www.ncbi.nlm.nih.gov/pubmed/27210870
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.05.004
work_keys_str_mv AT il10592wèidiǎnaajīyīnxíngduìhla1010quánxiānghéwúguāngōngzhěyìjīyīnzàoxuègànxìbāoyízhíyùhòudeyǐngxiǎng
AT il10592wèidiǎnaajīyīnxíngduìhla1010quánxiānghéwúguāngōngzhěyìjīyīnzàoxuègànxìbāoyízhíyùhòudeyǐngxiǎng
AT il10592wèidiǎnaajīyīnxíngduìhla1010quánxiānghéwúguāngōngzhěyìjīyīnzàoxuègànxìbāoyízhíyùhòudeyǐngxiǎng
AT il10592wèidiǎnaajīyīnxíngduìhla1010quánxiānghéwúguāngōngzhěyìjīyīnzàoxuègànxìbāoyízhíyùhòudeyǐngxiǎng
AT il10592wèidiǎnaajīyīnxíngduìhla1010quánxiānghéwúguāngōngzhěyìjīyīnzàoxuègànxìbāoyízhíyùhòudeyǐngxiǎng
AT il10592wèidiǎnaajīyīnxíngduìhla1010quánxiānghéwúguāngōngzhěyìjīyīnzàoxuègànxìbāoyízhíyùhòudeyǐngxiǎng